{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:24:31Z","timestamp":1761715471749,"version":"build-2065373602"},"reference-count":13,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Neben der Herzinsuffizienz an sich sind auch die begleitenden Erkrankungen wie Diabetes, Niereninsuffizienz, chronisch-obstruktive Lungenerkrankung (COPD) und Vorhofflimmern prognoseentscheidend, weshalb auch diese einer ad\u00e4quaten Therapie bed\u00fcrfen.<\/jats:p>\n                  <jats:p>Die Herzinsuffizienz-Therapie besteht aus 4 S\u00e4ulen, zumindest bei Herzinsuffizienz mit reduzierter Pumpfunktion: Betablocker, Sacubitril\/Valsartan (bzw. ACE-Hemmer), Mineralokortikoid-Rezeptor-Antagonisten und SGLT-2-Inhibitoren. Bei Herzinsuffizienz mit reduzierter Pumpfunktion sind sie prognoseverbessernd. Die Therapie von Komorbidit\u00e4ten wie etwa Eisenmangel ist entscheidend.<\/jats:p>\n                  <jats:p>Auch Eisenmangel hat eine hohe Pr\u00e4valenz. Im klinischen Alltag und auch in den meisten Studien werden vorwiegend Eisen(III)-Carboxymaltose und Eisen(III)-Derisomaltose zur intraven\u00f6sen Substitution verwendet. Hierbei liegt die durchschnittlich ben\u00f6tigte Dosis bei 1000\u20131500mg.<\/jats:p>","DOI":"10.1055\/a-2502-2024","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:58:13Z","timestamp":1761695893000},"page":"1341-1348","source":"Crossref","is-referenced-by-count":0,"title":["Herzinsuffizienz in Deutschland: Epidemiologie und neueste Entwicklungen"],"prefix":"10.1055","volume":"150","author":[{"given":"Josefine","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie und Pneumologie, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Kardiologie und Pneumologie, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen"},{"name":"DZHK \u2013 Standort Niedersachsen (Deutsches Zentrum f\u00fcr Herz- und Kreislaufforschung e.V.), Niedersachsen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/1474515120915040","article-title":"Caring experiences of family caregivers of patients with heart failure: A meta-ethnographic review of the past 10 years","volume":"19","author":"EY Kim","year":"2020","journal-title":"Eur J Cardiovasc Nurs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019","volume":"23","author":"PM Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","article-title":"Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)","volume":"34","author":"S Fulster","year":"2013","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/jcsm.12603","article-title":"Muscle wasting as an independent predictor of survival in patients with chronic heart failure","volume":"11","author":"S von Haehling","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1055\/a-2447-7654","article-title":"Instabile Herzinsuffizienz: Wie lassen sich h\u00e4ufige Krankenhausaufnahmen vermeiden?","volume":"150","author":"S von Haehling","year":"2025","journal-title":"Dtsch Med Wochenschr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"JJV McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction","volume":"7","author":"G Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2024.10.024","article-title":"Translating evidence into practice: Managing electrolyte imbalances and iron deficiency in heart failure","volume":"131","author":"R Sato","year":"2025","journal-title":"Eur J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"S von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric Carboxymaltose in Heart Failure with Iron Deficiency","volume":"389","author":"RJ Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry","volume":"106","author":"S von Haehling","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","article-title":"Redefining Iron Deficiency in Patients With Chronic Heart Failure","volume":"150","author":"M Packer","year":"2024","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/heartjnl-2022-322030","article-title":"Treating iron deficiency in patients with heart failure: what, why, when, how, where and who","volume":"110","author":"FJ Graham","year":"2024","journal-title":"Heart"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2502-2024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:58:15Z","timestamp":1761695895000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2502-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":13,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2502-2024","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}